Impact of genetic polymorphisms on chemotherapy toxicity in childhood acute lymphoblastic leukemia
Open Access
- 1 January 2012
- journal article
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 3, 249
- https://doi.org/10.3389/fgene.2012.00249
Abstract
The efficacy of chemotherapy in pediatric acute lymphoblastic leukemia (ALL) patients has significantly increased in the last 20 years; as a result, the focus of research is slowly shifting from trying to increase survival rates to reduce chemotherapy-related toxicity. At the present time, the cornerstone of therapy for ALL is still formed by a reduced number of drugs with a highly toxic profile. In recent years, a number of genetic polymorphisms have been identified that can play a significant role in modifying the pharmacokinetics and pharmacodynamics of these drugs. The best example is that of the TPMT gene, whose genotyping is being incorporated to clinical practice in order to individualize doses of mercaptopurine. However, there are additional genes that are relevant for the metabolism, activity, and/or transport of other chemotherapy drugs that are widely use in ALL, such as methotrexate, cyclophosphamide, vincristine, L-asparaginase, etoposide, cytarabine, or cytotoxic antibiotics. These genes can also be affected by genetic alterations that could therefore have clinical consequences. In this review we will discuss recent data on this field, with special focus on those polymorphisms that could be used in clinical practice to tailor chemotherapy for ALL in order to reduce the occurrence of serious adverse effects.Keywords
This publication has 101 references indexed in Scilit:
- Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine DosingClinical Pharmacology & Therapeutics, 2011
- A genome-wide approach identifies that the aspartate metabolism pathway contributes to asparaginase sensitivityLeukemia, 2010
- Association of cyclophosphamide drug–metabolizing enzyme polymorphisms and chemotherapy-related ovarian failure in breast cancer survivorsFertility and Sterility, 2010
- Genetic Variations in GRIA1 on Chromosome 5q33 Related to Asparaginase HypersensitivityClinical Pharmacology & Therapeutics, 2010
- Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamideBritish Journal of Cancer, 2010
- Identification of genomic regions contributing to etoposide-induced cytotoxicityHuman Genetics, 2008
- Genetic Polymorphism of Inosine Triphosphate Pyrophosphatase Is a Determinant of Mercaptopurine Metabolism and Toxicity During Treatment for Acute Lymphoblastic LeukemiaClinical Pharmacology & Therapeutics, 2008
- Childhood central nervous system leukemia: historical perspectives, current therapy, and acute neurological sequelaeNeuroradiology, 2007
- A genome-wide approach to identify genetic variants that contribute to etoposide-induced cytotoxicityProceedings of the National Academy of Sciences of the United States of America, 2007
- A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent‐onset rheumatoid arthritisArthritis & Rheumatism, 2007